Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05873062 · ClinicalTrials.gov registry record · Phase 1
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK
A Phase 1 study, sponsored by Autifony Therapeutics Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT05873062 is a Phase 1 study that has completed, run by Autifony Therapeutics Limited. The registered enrollment target is 6 participants.
The verdict
NCT05873062, a Phase 1 study, has completed, sponsored by Autifony Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled, crossover study to assess the safety, tolerability, and pharmacokinetics of single doses of AUT00201 at 100 mg or matching placebo in patients with myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK).
Interventions
- DRUG Placebo
- DRUG AUT00201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-05-12 |
| Est. Completion | 2024-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05873062
The ClinicalTrials.gov registry entry for NCT05873062 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Autifony Therapeutics Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05873062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05873062 about?
NCT05873062 is a clinical study titled "Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK". A randomized, double-blind, placebo-controlled, crossover study to assess the safety, tolerability, and pharmacokinetics of single doses of AUT00201 at 100 mg or matching placebo in patients with myoclonus epilepsy and ataxia due to potassium channel mutation (MEAK).
What is the current status of trial NCT05873062?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2023-05-12. Estimated completion is 2024-05-01.
What interventions are being tested in trial NCT05873062?
The interventions under investigation include: Placebo (DRUG), AUT00201 (DRUG).
Who is sponsoring clinical trial NCT05873062?
This trial is sponsored by Autifony Therapeutics Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.